

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

ELSEVIER

Contents lists available at ScienceDirect

Preventive Medicine Reports

journal homepage: www.elsevier.com/locate/pmedr



Correspondence

Response to "Speculation vs. evidence in the association between e-cigarette use and COVID-19"

We thank the editors for the opportunity to respond to Drs. Farsalinos and Niaura's comments (Farsalinos and Niaura, in press). They raise three main concerns about our report (Soule et al., 2020) and the potential adverse effects of electronic cigarette (e-cigarette) use and the COVID-19 pandemic. They contend that our report was "based on irrelevant and erroneously cited evidence", that "lipoid pneumonia is a treatable condition," and that we "grossly mis-presented a blog post" by the first author (Dr. Farsalinos).

We confirm that our cited literature was chosen carefully and based on its high clinical and basic research impact that supports detrimental effects of e-cigarette use on lung immunity. As our authorship team includes a practicing pulmonary and critical care physician (Dr. Kheradmand), we can testify that respiratory failure associated with chronic e-cigarette use is characterized by the recruitment of macrophages into the lungs that uptake abnormal surfactant lipids, as demonstrated by Madison et al., (2019). Filling the alveoli with dysfunctional macrophages can cause a severe life-threatening condition that impairs gas exchange and requires medical attention. The notion that respiratory diseases related to e-cigarette use do not occur is false and is unethical to promote.

Criticisms of Gaiha et al., (2020) by Farsalinos and Niaura based on findings they find "implausible" and "probably represent serious response bias" (emphasis added) are speculative. We look forward to seeing data that address the speculation introduced regarding Gaiha et al. (2020)'s findings.

Finally, when Soule et al. (2020) write "However, one of the empirical reports to which the text refers is from a 1980 U.S. Environmental Protection Agency document..." the phrase "the text" does not refer to a blog post by Farsalinos (Farsalinos, 2020), but rather refers to a different online document that we cite (Vaping and Coronavirus, 2020). The text of that online document (Vaping and Coronavirus, 2020) does refer to the U.S. Environmental Protection Agency report which, as Farsalinos and Niaura suggest, is irrelevant to propylene glycol inhalation via e-cigarette use because it refers to disinfecting room air from air sanitizers and demonstrates how media continues to spread misinformation regarding how e-cigarette use could be protective for COVID-19 outcomes. We apologize if this wording confused Farsalinos and Niaura.

We maintain that health practitioners should be aware of the association of e-cigarette use and COVID-19 outcomes as well as the spread of misinformation regarding speculations that e-cigarette use may be protective for COVID-19 outcomes.

Funding and author disclosures

This research was supported by grant number U54DA036105 from the National Institute on Drug Abuse of the National Institutes of Health and the Center for Tobacco Products of the U.S. Food and Drug

Administration. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the FDA. E. Soule and T. Eissenberg are named on a patent application for a smartphone app that determines electronic cigarette device and liquid characteristics. T. Eissenberg is a paid consultant in litigation against the tobacco industry and also against the electronic cigarette industry and is named on a patent for a device that measures the puffing behavior of electronic cigarette users.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Farsalinos, K., Niaura, R., 2020. Speculation vs. evidence in the association between ecigarette use and COVID-19: a response to Soule et al. Prev. Med. Rep. (In press).

Farsalinos K. Smoking, vaping and the coronavirus (COVID-19) epidemic: rumors vs. evidence. E-cigarette research. Accessed September 24, 2020. http://www.ecigarette-research.org/research/index.php/whats-new/2020/278-corona.

Gaiha, S.M., Cheng, J., Halpern-Felsher, B., 2020. Association between youth smoking, electronic cigarette use, and COVID-19. J. Adoles. Health 67 (4), 519–523. https://doi.org/10.1016/j.jadohealth.2020.07.002.

Madison, M.C., Landers, C.T., Gu, B.-H., et al., 2019. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J. Clin. Invest 129 (10), 4290–4304. https://doi.org/10.1172/JCI128531.

Soule, E.K., Kheradmand, F., Eissenberg, T., 2020. Health practitioners should caution about misinformation and association of adverse effects of electronic cigarette use and COVID-19. Prevent. Med. Rep. 20, 101255. https://doi.org/10.1016/j. pmedr.2020.101255.

Vaping and Coronavirus: What We Know and What We Don't. Vaping360. Accessed May 20, 2020. https://vaping360.com/vape-news/89213/vaping-and-coronavirus-what-we-know- and-what-we-dont/.

Eric K. Soule

Department of Health Education and Promotion, College of Health and Human Performance, East Carolina University, Greenville, NC, USA Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA

Farrah Kheradmand

Department of Medicine, Baylor College of Medicine, & Michael E. DeBakey VA Center, US Department of Veterans Affairs, Houston, TX 77030, USA

Thomas Eissenberg

Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA

Department of Psychology, College of Humanities and Sciences, Virginia
Commonwealth University, Richmond, VA, USA

https://doi.org/10.1016/j.pmedr.2021.101322

Received 30 December 2020; Received in revised form 30 December 2020; Accepted 17 January 2021 Available online 11 August 2021

* Corresponding author at: Department of Health Education and Promotion, 1000 East 1st Street, East Carolina University, Greenville, NC 27858, USA.

E-mail address: soulee18@ecu.edu (E.K. Soule).